Barclays Lowers Aveanna Healthcare (NASDAQ:AVAH) Price Target to $9.50

Aveanna Healthcare (NASDAQ:AVAH) had its price target dropped by research analysts at Barclays from $11.00 to $9.50 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. Barclays‘s target price suggests a potential upside of 41.69% from the stock’s previous close.

Other equities research analysts also recently issued reports about the stock. Zacks Research downgraded shares of Aveanna Healthcare from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 3rd. Royal Bank Of Canada dropped their price target on Aveanna Healthcare from $11.00 to $9.00 and set a “sector perform” rating on the stock in a research note on Monday. UBS Group upped their price objective on shares of Aveanna Healthcare from $9.50 to $10.00 and gave the company a “neutral” rating in a report on Thursday, January 15th. Raymond James Financial raised shares of Aveanna Healthcare from an “outperform” rating to a “strong-buy” rating and set a $13.00 target price for the company in a report on Friday, March 20th. Finally, BMO Capital Markets cut their price objective on shares of Aveanna Healthcare from $11.00 to $10.00 and set an “outperform” rating for the company in a research report on Friday, March 20th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.38.

Aveanna Healthcare Price Performance

NASDAQ:AVAH opened at $6.71 on Wednesday. The stock’s 50-day simple moving average is $7.76 and its 200 day simple moving average is $8.47. Aveanna Healthcare has a 52-week low of $3.73 and a 52-week high of $10.32. The company has a debt-to-equity ratio of 6.62, a quick ratio of 1.32 and a current ratio of 1.32. The company has a market cap of $1.46 billion, a P/E ratio of 6.55 and a beta of 2.07.

Insider Buying and Selling at Aveanna Healthcare

In other Aveanna Healthcare news, CEO Jeff Shaner sold 173,225 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $7.21, for a total value of $1,248,952.25. Following the completion of the transaction, the chief executive officer owned 2,650,892 shares in the company, valued at $19,112,931.32. This represents a 6.13% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matthew Buckhalter sold 13,512 shares of the business’s stock in a transaction dated Thursday, February 19th. The stock was sold at an average price of $7.21, for a total transaction of $97,421.52. Following the completion of the transaction, the chief financial officer directly owned 529,243 shares in the company, valued at $3,815,842.03. This trade represents a 2.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 998,595 shares of company stock valued at $7,567,770 over the last ninety days. Insiders own 7.00% of the company’s stock.

Hedge Funds Weigh In On Aveanna Healthcare

Institutional investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd lifted its holdings in Aveanna Healthcare by 8.9% during the third quarter. Dynamic Technology Lab Private Ltd now owns 14,149 shares of the company’s stock valued at $126,000 after purchasing an additional 1,151 shares during the last quarter. Barclays PLC boosted its stake in Aveanna Healthcare by 0.8% during the third quarter. Barclays PLC now owns 179,359 shares of the company’s stock valued at $1,591,000 after buying an additional 1,366 shares during the period. Franklin Resources Inc. increased its stake in Aveanna Healthcare by 4.5% in the 3rd quarter. Franklin Resources Inc. now owns 35,630 shares of the company’s stock worth $316,000 after acquiring an additional 1,528 shares during the last quarter. Intech Investment Management LLC raised its holdings in shares of Aveanna Healthcare by 9.8% in the 4th quarter. Intech Investment Management LLC now owns 19,483 shares of the company’s stock valued at $159,000 after acquiring an additional 1,739 shares in the last quarter. Finally, Balboa Wealth Partners grew its holdings in shares of Aveanna Healthcare by 13.5% during the fourth quarter. Balboa Wealth Partners now owns 16,890 shares of the company’s stock worth $138,000 after purchasing an additional 2,007 shares in the last quarter. Hedge funds and other institutional investors own 87.96% of the company’s stock.

About Aveanna Healthcare

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.